[go: up one dir, main page]

MX2022001261A - Derivados de dihidropirimidina y usos de los mismos en el tratamiento de infeccion por vhb o de enfermedades inducidas por vhb. - Google Patents

Derivados de dihidropirimidina y usos de los mismos en el tratamiento de infeccion por vhb o de enfermedades inducidas por vhb.

Info

Publication number
MX2022001261A
MX2022001261A MX2022001261A MX2022001261A MX2022001261A MX 2022001261 A MX2022001261 A MX 2022001261A MX 2022001261 A MX2022001261 A MX 2022001261A MX 2022001261 A MX2022001261 A MX 2022001261A MX 2022001261 A MX2022001261 A MX 2022001261A
Authority
MX
Mexico
Prior art keywords
hbv
treatment
induced diseases
infection
dihydropyrimidine derivatives
Prior art date
Application number
MX2022001261A
Other languages
English (en)
Inventor
Zhanling Cheng
Zhiguo Liu
Yimin Jiang
Linglong Kong
Jianping Wu
Yanping Xu
Gang Deng
Chao Liang
Xiangjun Deng
Original Assignee
Janssen Sciences Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Unlimited Co filed Critical Janssen Sciences Ireland Unlimited Co
Publication of MX2022001261A publication Critical patent/MX2022001261A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La solicitud describe derivados de dihidropirimidina que son útiles en el tratamiento o la prevención de una infección por VHB o de enfermedades inducidas por VHB, más particularmente de una infección crónica por VHB o de enfermedades inducidas por una infección crónica por VHB, así como aplicaciones farmacéuticas o médicas de los mismos.
MX2022001261A 2019-07-31 2020-07-30 Derivados de dihidropirimidina y usos de los mismos en el tratamiento de infeccion por vhb o de enfermedades inducidas por vhb. MX2022001261A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2019098569 2019-07-31
CN2020077163 2020-02-28
CN2020096777 2020-06-18
PCT/CN2020/105764 WO2021018237A1 (en) 2019-07-31 2020-07-30 Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases

Publications (1)

Publication Number Publication Date
MX2022001261A true MX2022001261A (es) 2022-05-03

Family

ID=74230289

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001261A MX2022001261A (es) 2019-07-31 2020-07-30 Derivados de dihidropirimidina y usos de los mismos en el tratamiento de infeccion por vhb o de enfermedades inducidas por vhb.

Country Status (11)

Country Link
US (1) US20230083012A1 (es)
EP (1) EP4003355A4 (es)
JP (1) JP2022542420A (es)
KR (1) KR20220041120A (es)
CN (1) CN114173787A (es)
AU (1) AU2020323092A1 (es)
BR (1) BR112022000971A2 (es)
CA (1) CA3146992A1 (es)
MX (1) MX2022001261A (es)
TW (1) TW202122392A (es)
WO (1) WO2021018237A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022161448A1 (en) * 2021-01-29 2022-08-04 Janssen Sciences Ireland Unlimited Company Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
US20240246978A1 (en) * 2021-02-05 2024-07-25 Hepagene Therapeutics (HK) Limited Phenyldihydropyrimidine compound and use thereof
CN114907355A (zh) * 2021-02-09 2022-08-16 上海维申医药有限公司 一种二氢嘧啶类化合物、其制备方法及其应用
WO2022257942A1 (en) 2021-06-09 2022-12-15 Janssen Sciences Ireland Unlimited Company Dihydropyrimidine derivatives and uses thereof in the treatment of hbv infection or of hbv-induced diseases
CN120383543A (zh) * 2025-06-06 2025-07-29 康龙化成手性医药技术(宁波)有限公司 一种4-氟-2-氮杂双环[2.1.1]己烷盐酸盐的合成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10012823A1 (de) * 2000-03-16 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
DE10013126A1 (de) * 2000-03-17 2001-09-20 Bayer Ag Arzneimittel gegen virale Erkrankungen
CN101575318B (zh) * 2009-06-25 2012-02-08 中国人民解放军军事医学科学院毒物药物研究所 二氢嘧啶类化合物及其用于制备治疗和/或预防病毒性疾病的药物的用途
US9487534B2 (en) * 2011-08-02 2016-11-08 Scripps Research Institute, A Not-For-Profit Public Benefit Corporation Of California Modulators of virus assembly as antiviral agents
KR20140143160A (ko) * 2012-03-31 2014-12-15 에프. 호프만-라 로슈 아게 B형 간염 바이러스 감염의 치료 및 예방을 위한 신규한 4-메틸-다이하이드로피리미딘
PL2888241T3 (pl) * 2012-08-24 2017-12-29 Sunshine Lake Pharma Co., Ltd. 2,4,5,6-Podstawione pochodne 3,6-dihydropirymidyny jako inhibitory polimerazy wirusa zapalenia wątroby typu B (HBV) do leczenia np. przewlekłego zapalenia wątroby
CN103664897B (zh) * 2012-09-01 2018-04-03 广东东阳光药业有限公司 二氢嘧啶类化合物及其在药物中的应用
CN103664925B (zh) * 2012-09-07 2018-01-23 广东东阳光药业有限公司 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用
CN103664899B (zh) * 2012-09-11 2017-06-16 广东东阳光药业有限公司 杂芳基取代的二氢嘧啶类化合物及其在药物中的应用
PT3114128T (pt) * 2014-03-07 2019-02-27 Hoffmann La Roche Novas heteroarildihidropirimidinas fundidas em 6 para o tratamento e profilaxia da infeção pelo vírus da hepatite b.
CA2950807C (en) * 2014-05-30 2022-05-31 Medshine Discovery Inc. Dihydropyrimido fused ring derivative as hbv inhibitor
CN107427514B (zh) * 2015-03-16 2021-07-13 豪夫迈·罗氏有限公司 使用tlr7激动剂和hbv衣壳装配抑制剂的组合治疗
WO2017064156A1 (en) * 2015-10-16 2017-04-20 F. Hoffmann-La Roche Ag Novel 6-fused and 2-heteroaryldihydropyrimidines for the treatment and prophylaxis of hepatitis b virus infection
AR107633A1 (es) * 2016-02-19 2018-05-16 Hoffmann La Roche Procedimiento para la preparación del ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxílico
BR112019004560A2 (pt) * 2016-09-13 2019-07-02 Hoffmann La Roche tratamento combinado com agonista de tlr7 e um inibidor de formação de capsídeo de hbv
CN107501257B (zh) * 2017-08-17 2020-05-29 山东大学 二氢嘧啶-三氮唑类衍生物及其制备方法与应用
CN108947996B (zh) * 2018-07-12 2022-01-18 山东大学 二氢嘧啶-磺酰胺类衍生物及其制备方法与应用

Also Published As

Publication number Publication date
KR20220041120A (ko) 2022-03-31
BR112022000971A2 (pt) 2022-06-07
TW202122392A (zh) 2021-06-16
JP2022542420A (ja) 2022-10-03
US20230083012A1 (en) 2023-03-16
EP4003355A1 (en) 2022-06-01
AU2020323092A1 (en) 2022-03-24
CA3146992A1 (en) 2021-02-04
EP4003355A4 (en) 2023-07-26
CN114173787A (zh) 2022-03-11
WO2021018237A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
MX2022001261A (es) Derivados de dihidropirimidina y usos de los mismos en el tratamiento de infeccion por vhb o de enfermedades inducidas por vhb.
MX2018002520A (es) Compuesto novedoso de pirazolo[3,4-d] pirimidina o sal del mismo.
NZ733174A (en) Quinazoline derivatives used to treat hiv
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
WO2016196776A3 (en) Inhibitors of bruton's tyrosine kinase
WO2016004305A3 (en) Inhibitors of bruton's tyrosine kinase
NZ732391A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
MX378726B (es) Uso de compuestos de tiazolida para la prevencion y tratamiento de enfermedades virales, cancer y enfermedades causadas por infecciones intracelulares.
SA523440384B1 (ar) مركبات الفوسفوليبيدات واستخداماتها
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
ZA202000375B (en) Compounds for the prevention and treatment of medical disorders and uses thereof
MX2021010145A (es) Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb.
MX2017003928A (es) Composiciones farmaceuticas de accion prolongada.
MX2018008640A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano.
WO2016086153A3 (en) Use of hsp90 inhibitors for the treatment of hiv infections and aids
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
EP3790866A4 (en) DIHYDROPYRIMIDINE DERIVATIVES AND THEIR USES IN THE TREATMENT OF HEPATITIS B VIRUS INFECTION OR HEPATITIS B VIRUS INDUCED DISEASES
MX2022001271A (es) Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.
PH12018500450A1 (en) Immunity enhancing agent for cancer by allergin-1 antagonist
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX382439B (es) Compuestos de carbapenem
MX2022001266A (es) Derivados de dihidropirimidina y usos de estos en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.
MA40805A (fr) Compositions pharmaceutiques à action prolongée contre l'hépatite c
UY39616A (es) Derivados de dihidropirimidina y usos de estos en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb
MX2021013594A (es) Derivados de amida utiles en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb.